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Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired syndrome characterized by 
intravascular hemolysis, thrombosis, and bone marrow failure. The disease is caused 
by a mutation in the PIG-A gene that leads to the lack of glycosylphosphatidylinositol- 
anchored complement regulatory molecules CD55 and CD59 on affected blood cell 
surfaces. In previous studies, spontaneous clinical remissions have been described. The 
disease manifestations are very heterogeneous, and we wanted to examine if true remis-
sions and disappearance of the clone occur. In a follow-up of a nation-wide cohort of 
106 Finnish patients with a PNH clone, we found six cases, where the clone disappeared 
or was clearly diminished. Two of the patients subsequently developed leukemia, while 
the other four are healthy and in clinical remission. According to our data, spontaneous 
remissions are not as frequent as described earlier. Since the disappearance of the PNH 
cell clone may indicate either a favorable or a poor outcome—remission or malignancy—
careful clinical monitoring in PNH is mandatory. Nevertheless, true remissions occur, 
and further studies are needed to understand the immunological background of this 
phenomenon and to obtain a better understanding of the natural history of the disease.
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inTrODUcTiOn
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired syndrome characterized by intravas-
cular hemolysis, thrombosis, and bone marrow (BM) failure (1). The disease is caused by a mutation 
in the PIG-A gene that leads to the lack of glycosylphosphatidylinositol (GPI)-anchored molecules, 
including the complement regulatory proteins CD55 and CD59 from the surface of a clonal lineage 
of blood cells (2–4). In addition, rare forms of PNH with mutations in the CD59 gene have been 
described indicating the key role of the absence of CD59 in the disease (5, 6).
The diagnosis of PNH is made by analyzing GPI-anchored molecules or the anchor itself on 
blood cells by flow cytometry. The disease course is often unpredictable, and the therapeutic options 
are limited. While in previous studies spontaneous remissions have been reported to occur in up to 
15–30% of cases (7, 8), there are only few detailed case reports published on these patients. Recently, 
four cases of spontaneous remission were described in two different studies (9, 10), but doubts exist 
whether remissions really occur in PNH patients. In particular, it would be important to distinguish 
Table 1 | Patients and treatments.
age at Pnh 
diagnosis (year)




Patient 1 23 years (1990)a 19 years (1986) Androgens, corticosteroids
Patient 2 56 years (1998) Hypoplastic BM
57 years (1999)
Androgens, corticosteroids
Patient 3 24 years (1998) 21 years (1995) Antithymocyte globulin, 
prednisolone, cyclosporine, 
granulocyte growth factor
Patient 4 25 years (1998) 19 years (1992) Cyclosporine, androgens
Patient 5 43 years (2000) 43 years (2000) Antithymocyte globulin, 
prednisolone, cyclosporine
Patient 6 44 years (1998) 43 years (1997) Prednisolone, cyclosporine
PNH, paroxysmal nocturnal hemoglobinuria; AA, aplastic anemia; BM, bone marrow.
aDiagnosis by Ham’s test. First flow cytometry in 2001. For further clinical information, 
please see the text.
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true remissions from other developing disorders, especially from 
malignancy, because in both cases the PNH diagnostics may give 
a negative result.
Because of the variable clinical course of PNH, we wanted 
to explore whether true spontaneous remissions occur in PNH 
in the Finnish patient material that we have collected during a 
long period of time. A nation-wide study of all PNH patients 
diagnosed in Finland since 1995 and an extended follow-up time 
(up to 20 years) have provided a unique opportunity to perform 
a detailed analysis of the course of the disease in our patients.
PaTienTs anD MeThODs
In a nation-wide project, we collected patients from all Health 
Care Districts in Finland (with a total population of 5.6 million). 
The sources of information included the Helsinki University 
Central Hospital Laboratory (HUSLAB) databases, flow cytom-
etry analysis of red blood cells (RBCs) and leukocytes, patients’ 
medical records, and a patient questionnaire. The patients were 
evaluated until September 2016, and the remission cases were 
followed until June 2017. In total, 106 patients with a CD59-
deficient cell clone in flow cytometry were included in the study.
Besides the flow cytometry analysis the laboratory parameters 
included levels of hemoglobin (Hb), lactate dehydrogenase, hap-
toglobin, erythrocytes, leukocytes, platelets, inflammation mark-
ers (CRP, ESR), D-dimer, fibrinogen, coagulation factor VIII, 
creatinine, and ventricular natriuretic peptide. In addition, the 
glomerular filtration rates and BM analyses were performed. The 
clinical data included the symptoms and conditions attributable 
to PNH: hemoglobinuria, thrombotic events, infections, fatigue, 
renal failure, pulmonary hypertension, abdominal pain, dyspha-
gia, dyspnea, erectile dysfunction, anemia, and the co-existence 
of PNH with aplastic anemia (AA), myelodysplastic syndrome 
(MDS), or leukemia.
An ethical permission for the study was provided by the coor-
dinating ethical committee at the Helsinki University Hospital 
Health Care District. A research permission was also obtained 
from the National Institute of Health and Welfare (THL, Helsinki, 
Finland), and the patients gave written informed consents for the 
study.
resUlTs
In a cohort of 106 Finnish patients with a PNH clone, we found 
6 cases, where the clone disappeared or clearly diminished (to a 
level equal or below 1.5%). Two of the six patients subsequently 
developed leukemia (acute myeloid leukemia and chronic 
myelomonocytic leukemia), while the other four are in clinical 
remission (Table 1).
Patient number 1 was diagnosed with AA in 1986 during a 
twin pregnancy. The patient had pre-eclampsia and a cesarean 
section was performed. The PNH diagnosis was made by Ham’s 
test in 1990 at the age of 23 years. The first flow cytometry test 
was performed in 2001 (24% CD59-negative erythrocytes) 
(Figure 1A). The patient was first treated with steroids without 
any positive outcome and with androgens for 2 years. In 1994, the 
patient was diagnosed with multiple sclerosis. In the mid 90s, the 
patient got several blood transfusions and twice more in 2005 and 
2006. No thrombotic complications occurred. The patient was 
given anticoagulation treatment. Low molecular-weight heparin 
was used postoperatively after a gynecologic operation in 2006, 
and since 2008 the patient used aspirin. In 2012, erythrocytes, 
monocytes, and neutrophils were analyzed by the flow cytometry 
test, and no PNH clone was detected. The patient had no longer 
signs of hemolysis. In the same year, however, the patient was 
diagnosed with MDS and later with acute myeloid leukemia. The 
patient died of leukemia in 2013 at the age of 45 years.
Case 2 (female) was diagnosed with PNH in 1998 at the age of 
56 years (30% CD59-negative erythrocytes by flow cytometry). At 
the time of diagnosis, the Hb level was 70 g/L, and the numbers 
of leukocytes 2.5 × 109/L and platelets 6 × 109/L. The patient had 
a tendency for bruising, petechiae, and bleeding on probing. In 
1999, the patient’s BM sample showed hypoplastic features. The 
patient was treated with corticosteroids from 1998 until 2005. 
Androgen treatment was stopped because of elevated liver values. 
The CD59-negative erythrocyte clone peaked in 1998 after which 
it gradually declined. In 1999, the patient received cyclosporine 
treatment, which had a good effect on the anemia. In 2007, the 
patient recurrently developed anemia and thrombocytopenia. At 
that time, the RBCs had a normal CD59 expression level on flow 
cytometry (Figure 1B). The BM sample showed myelodysplastic 
changes and a systemic mastocytosis with c-KIT mutation was 
observed. In 2010, the patient was diagnosed with chronic myelo-
monocytic leukemia and azacytidine treatment was started. In 
2011, the patient died because of acute ischemic heart disease 
during the leukemia treatment.
Case 3 (female) was diagnosed with AA in 1995 at the age of 
21 years. At the time of diagnosis, the Hb level was 50 g/L, leuko-
cytes 1.9 × 109/L, and platelets 8 × 109/L. The patient was treated 
with antithymocyte globulin, prednisolone, cyclosporine, and 
granulocyte growth factor. In 1996, 8% of the erythrocytes were 
CD59 deficient. When the flow cytometry was performed next 
time in 1998, 50% of the erythrocytes was type I CD59-deficient 
cells and 30% type II (partially CD59 deficient) cells (Figure 1C). 
No thrombotic complications or bleeding have occurred at any 
time of the disease history. The lactate dehydrogenase level was 
FigUre 1 | The percentage of totally and partially CD59-deficient red blood cells in patients 1–6 [(a–F), respectively]. For patients 1, 3, 5, and 6 who had 
intravascular hemolysis, the lactate dehydrogenase levels (LD) are shown at right on the Y-axis as values in relation to the upper limit of normal (a,c,e,F). Patients 1 
and 2 (a,b) suffered from leukemia and subsequently died. Patients 3–6 are in remission.
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elevated earlier, but has been normal since 2006 (Figure 1C). The 
patient had two deliveries, in 2003 and 2007. During the first 
delivery, the patient was given blood transfusions and suffered 
from postpartum endometritis. The second delivery was without 
complications. In the 1990s, the patient had periods of hemoglo-
binuria. In 2012, the cyclosporine treatment was stopped, and 
only 0.2% of the erythrocytes were CD59 negative. Since 2013 
the expression of CD59 has been normal on erythrocytes and 
the GPI-negative clone in neutrophils and monocytes has been 
0.3–0.6% and the patient is symptom free.
Patient 4 (male) was diagnosed with AA in 1992, and the 
PNH diagnosis was made in 1998 when the patient was 25 years 
old (10% CD59-negative erythrocytes in flow cytometry). 
Before that the patient had had a small CD59-negative RBC 
clone (1.7–7%) since 1996. In 1992, the patient got several RBC 
and platelet transfusions. Cyclosporine and androgen treatment 
were started in 1992 with a good response leading to recovery 
from the cytopenias. The androgen treatment was discontinued 
in 2003 and cyclosporine treatment in 2012. Since then the 
patient has had no symptoms, and the laboratory parameters 
have been in the normal range. In 2010, CD59 expression on the 
erythrocytes was normal. In later controls, the expression has 
been either fully normal or the CD59-negative erythrocyte cell 
clone has been small (between 0.2 and 1.4%) (Figure 1D). The 
GPI-negative clone in neutrophils and monocytes has been in 
the range 0.2–1.5%.
Case 5 (male) was diagnosed with AA and PNH in 2000 at 
the age of 43 years. Fifty-three percent of the erythrocytes were 
totally CD59 deficient. In addition, 10% had a decreased expres-
sion (type II cells). In the BM sample, the cellularity was 25–30% 
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of normal. At the time of diagnosis, the Hb level was 54  g/L, 
neutrophils 0.3  ×  109/L, and platelets 26  ×  109/L. The patient 
was initially treated with prednisolone for a short time. Later, 
the patient was given antithymocyte globulin treatment and 
cyclosporine for 1 year. Initially, the response to the immunosup-
pressive treatment was not sufficient, and an allogeneic stem cell 
transplantation with register donor was already being planned. In 
2002, the transplantation was canceled because of a late response 
to the treatment. At that point, the Hb level was 122 g/L, neu-
trophils 0.77 × 109/L, and platelets 96 × 109/L. The patient had 
hemolysis and hemoglobinuria, fatigue, and erectile dysfunction. 
No thrombotic complications occurred. The anemia was com-
pensated, and there was no transfusion dependency. Since 2009 
the patient has been symptom free and the lab values stable, Hb 
level 155 g/L. The PNH clone has been declining (Figure 1E). In 
2017, it was below 1% in both RBCs and neutrophils.
Patient 6 (male) was diagnosed with AA at the age of 43 years 
in 1997. At that time, the patient had pancytopenia and 5.4% of 
RBCs were CD59 deficient. The patient was treated with cyclo-
sporine with a good response. In 1998, the size of the PNH clone 
was 52%. The patient had tendency for bruising, hemoglobinuria, 
and erectile dysfunction, but no thrombosis. Since 2009 the LD 
values normalized, and the patient did not report hemoglobi-
nuria any more. In 2010, the size of the PNH clone had already 
clearly diminished, and in 2013, it was 0.3% in RBCs and 0.8% in 
neutrophils (Figure 1F).
Among all the six patients, the median time from the diagnosis 
until the remission was 12.5  years (range 6–15  years). For the 
two patients who developed leukemia, the diagnosis was made 
26 and 12 years after the initial PNH/AA diagnosis, respectively. 
In one patient, the CD59-deficient cell clone disappeared 3 years 
earlier, and for the other one in the same year leukemia was 
diagnosed. For all six patients, the median CD59-deficient RBC 
clone size was 64% at highest (range 30–91%) (Figure 1). Four of 
the patients had classical PNH with signs of hemolysis. None of 
the patients received eculizumab therapy since it was not avail-
able at the time of diagnosis. All patients had underlying AA or 
another type of BM failure. Four of the patients were treated with 
cyclosporine, three with androgens, and five with corticosteroids. 
Two of the remission cases also got antithymocyte globulin, and 
one was given granulocyte growth factor. None of the patients 
was heavily transfusion dependent.
DiscUssiOn
Paroxysmal nocturnal hemoglobinuria is a potentially serious 
illness with variable manifestations and outcomes. Reliably 
defined complete remissions from the disease have only rarely 
been described, and doubt exists whether a permanent cure 
from the disease can occur. In Finland, it has been possible to 
conduct a nation-wide study because it has a relatively small 
population (5.6 million) with a comprehensive public healthcare 
system, where rare cases are centralized to specialized healthcare. 
Thus, for this study, we were able to collect all patients diagnosed 
with PNH from a period of over 20 years, altogether 106 PNH 
patients. Indeed, among these we found six cases, where the 
PNH cell clones disappeared. In four cases, this was accompanied 
with spontaneous clinical remission, as well. By contrast, in two 
other cases—showing apparently the disappearance of the PNH 
clone—the disease developed into malignancy.
Our data show that spontaneous remissions are not as 
frequent as previously described, and the disappearance of the 
PNH cell clone can be related to dramatically different outcomes. 
In a Spanish patient cohort, spontaneous remission was reported 
to occur in as many as 30% of the patients (17/56), but the cases 
were not characterized further, and the spontaneous remission 
was not defined (8). We considered that the patients were in 
remission when they had no clinical signs of disease (i.e., no 
cytopenias, signs of hemolysis, or thrombosis) and no flow 
cytometry evidence for PNH. For the latter, a threshold level 
of 1.5% for GPI-anchor negative RBCs was employed, because 
levels lower than this may be artifacts due to staining or trans-
portation. Small PNH-like clones may also be seen in healthy 
individuals (11). In a British material from the year 1995, spon-
taneous clinical remissions were reported in 15% of the patients 
(12/80) (7). The patients had a negative Ham’s test. In five cases, 
flow cytometry was later performed, and in all cases, the RBCs 
expressed normal levels of GPI-linked proteins. However, pos-
sible misdiagnoses with the earlier less specific Ham’s test cannot 
be excluded.
Nevertheless, as our study shows, true remissions occur, but the 
patients need to be carefully followed up for a potential emergence 
of malignancy. Among the six patients, where the PNH clone 
disappeared, four are healthy and have no treatment. The actual 
mechanisms or the reasons for the remissions are unknown. They 
may be spontaneous, have an immunological background, or be 
related to therapy. A proposed explanation has been that the PNH 
clone has a finite lifespan and that normal stem cells are capable 
of repopulating the BM (7). Recently, a case was described, where 
a decrease in the PNH clone did not restore normal hematopoiesis 
but instead was associated with clonal replacement (9). Notably, 
however, in this case, the PNH clone did not disappear but 
remained at a 15% level. All of our six patients had an underly-
ing BM failure. Patients received treatments (e.g., cyclosporine, 
androgens, steroids, CSF, or antithymocyte globulin) that may 
also have affected the PNH cell clone or the cell clone could have 
lost its growth advantage (12) after repopulating the BM.
Paroxysmal nocturnal hemoglobinuria has previously been 
considered to be a monoclonal disorder, and the expansion of 
the GPI-deficient clone has been explained by extrinsic fac-
tors (13). Recent studies have shown that multiple clones are 
present, and a number of additional somatic mutations in the 
PNH clones have been detected (14, 15). The latter may lead 
to clonal selection. Partially, CD59-deficient type II cells are 
thought to emerge because of only a partially defective or absent 
PIG-A enzyme. As PNH is currently regarded as a multiclonal 
disease with clonal hierarchy (14) and a large number of cells 
are involved, a repairing mutation can not be the explanation 
for remission. In our view, the most likely possibility is that the 
immune system is eliminating cells through complement attack 
and/or by the formation of antibodies or by a cell-mediated 
immune response. If antibodies against cells develop, as may 
occur after blood transfusions, the clearance of CD59-negative 
cells could be further boosted. Cells lacking CD59 and CD55 
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would, after all, be more susceptible to complement-mediated 
clearance. Some antibodies may even be targeted against unique 
epitopes on GPI-anchor deficient cells.
Paroxysmal nocturnal hemoglobinuria is known to be a very 
variable disease, and this is also typical among the remission 
cases. The fact that the clone disappears may be related to dif-
ferent outcomes, total recovery, or BM suppression and devel-
opment of leukemia. This provides a challenge to the clinician. 
Careful follow-up is needed to determine the direction to which 
the disease is progressing. Further studies on the mechanisms of 
spontaneous remissions could also provide clues for finding a 
curative treatment for PNH in the future.
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